The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition.
1. INTRODUCTION - p. 439 2. EPIDEMIOLOGY - p. 439 3. ETIOLOGIC FACTORS AND PREDISPOSING CONDITIONS - p. 440 4. APPLIED ANATOMY AND HISTOLOGY - p. 442 5. NATURAL HISTORY AND PATTERNS OF FAILURE - p. 443 6. CLINICAL PRESENTATION - p. 444 7. DIAGNOSTIC STUDIES AND PRETREATMENT STAGING TOOLS - p. 444 8. STAGING GUIDELINES - p. 445 9. BIOMARKERS - p. 445 10. TREATMENT - p. 447 11. PREDICTORS OF TREATMENT RESPONSE - p. 464 12. PALLIATION OF ESOPHAGEAL CANCER WITH RADIATION THERAPY - p. 466 13. RADIOTHERAPY TECHNIQUES - p. 467 14. TREATMENT OF METASTATIC DISEASE - p. 469 15. 34. Cancer of the Stomach - p. 487 16. 35. Cancer of the Pancreas - p. 509 17. 36. Cancer of the Liver - p. 544 18. 37. Cancer of the Biliary Tree - p. 570 19. 38. Small Bowel Cancer - p. 590 20. 39. Gastrointestinal Stromal Tumor - p. 604 21. 40. Cancer of the Colon - p. 618 22. INTRODUCTION - p. 618 23. MOLECULAR BIOLOGY - p. 618 24. MULTISTEP MODELS OF COLORECTAL CANCER AND GENETIC INSTABILITY - p. 618 25. MUTATIONAL AND EPIGENETIC LANDSCAPES IN COLORECTAL CANCER - p. 618 26. ONCOGENE AND TUMOR SUPPRESSOR GENE MUTATIONS IN COLORECTAL CANCER PROGRESSION - p. 620 27. EPIDEMIOLOGY - p. 621 28. ETIOLOGY: GENETIC AND ENVIRONMENTAL RISK FACTORS - p. 622 29. FAMILIAL COLORECTAL CANCER - p. 625 30. ANATOMY OF THE COLON - p. 627 31. DIAGNOSIS OF COLORECTAL CANCER - p. 628 32. SCREENING FOR COLORECTAL CANCER - p. 629 33. STAGING AND PROGNOSIS OF COLORECTAL CANCER - p. 630 34. APPROACHES TO SURGICAL RESECTION OF COLON CANCER - p. 636 35. SURGICAL MANAGEMENT OF COMPLICATIONS FROM PRIMARY COLON CANCER - p. 639 36. LAPAROSCOPIC COLON RESECTION - p. 640 37. POLYPS AND STAGE I COLON CANCER - p. 641 38. STAGE II AND STAGE III COLON CANCER - p. 641 39. TREATMENT OF STAGE II PATIENTS - p. 644 40. TREATMENT OPTIONS FOR STAGE III PATIENTS - p. 647 41. INVESTIGATIONAL ADJUVANT APPROACHES - p. 648 42. FOLLOW-UP AFTER MANAGEMENT OF COLON CANCER WITH CURATIVE INTENT - p. 649 43. SURGICAL MANAGEMENT OF STAGE IV DISEASE - p. 650 44. MANAGEMENT OF UNRESECTABLE METASTATIC DISEASE - p. 651 45. MOLECULAR PREDICTIVE MARKERS - p. 667 46. 41. Cancer of the Rectum - p. 678 47. 42. Cancer of the Anal Region - p. 708 48. 43. Cancer of the Kidney - p. 729 49. 44. Cancer of the Bladder, Ureter, and Renal Pelvis - p. 756 50. 45. Cancer of the Prostate - p. 784 51. INTRODUCTION - p. 784 52. EPIDEMIOLOGY - p. 784 53. ANATOMY AND PATHOLOGY - p. 786 54. SCREENING - p. 791 55. DIAGNOSIS AND WORKUP - p. 792 56. RISK STRATIFICATION - p. 803 57. TREATMENT OF PROSTATE CANCER - p. 806 58. MANAGEMENT OF CLINICAL DISEASE STATES - p. 815 59. Clinically Localized Prostate Cancer - p. 815 60. Clinical Node Positive Disease - p. 821 61. Recurrent Prostate Cancer - p. 821 62. Metastatic Hormone-sensitive Disease - p. 822 63. Castrate-resistant Disease - p. 825 64. Variant Prostate Cancer - p. 830 65. Bone Supportive Agents - p. 831 66. FUTURE DIRECTIONS - p. 832 67. 46. Cancer of the Urethra and Penis - p. 846 68. 47. Cancer of the Testis - p. 856 69. 48. Cancer of the Cervix - p. 874 70. 49. Cancer of the Vagina and Vulva - p. 902 71. 50. Cancer of the Uterine Body - p. 917 72. 51. Gestational Trophoblastic Neoplasia - p. 935 73. 52. Ovarian Cancer - p. 941 74. 53. Malignant Tumors of the Breast - p. 968 75. INCIDENCE AND ETIOLOGY - p. 968 76. SCREENING AND PREVENTION FOR WOMEN AT HIGH RISK OF BREAST CANCER - p. 970 77. ANATOMY AND PATHOLOGY - p. 971 78. DIAGNOSIS AND BIOPSY - p. 975 79. STAGING - p. 976 80. MANAGEMENT BY STAGE: DUCTAL CARCINOMA IN SITU - p. 976 81. MANAGEMENT BY STAGE: PRIMARY OPERABLE INVASIVE BREAST CANCER - p. 982 82. MANAGEMENT BY STAGE: ADJUVANT SYSTEMIC THERAPY - p. 993 83. MANAGEMENT BY STAGE: SPECIAL CONSIDERATIONS - p. 999 84. MANAGEMENT BY STAGE: METASTATIC DISEASE - p. 1003 85. ACKNOWLEDGMENT - p. 1007 86. 54. Thyroid Tumors - p. 1019 87. 55. Parathyroid Tumors - p. 1032 88. 56. Adrenal Tumors - p. 1038 89. 57. Pancreatic Neuroendocrine Neoplasms - p. 1048 90. 58. Carcinoid Tumors and the Carcinoid Syndrome - p. 1064 91. 59. Multiple Endocrine Neoplasia - p. 1073 92. 60. Soft Tissue Sarcoma - p. 1080 93. INTRODUCTION - p. 1080 94. INCIDENCE AND ETIOLOGY - p. 1080 95. ANATOMIC AND AGE DISTRIBUTION AND PATHOLOGY - p. 1081 96. CLINICAL AND PATHOLOGIC FEATURES OF SPECIFIC SOFT TISSUE TUMOR TYPES - p. 1084 97. DIAGNOSIS AND STAGING - p. 1102 98. MANAGEMENT BY PRESENTATION STATUS, EXTENT OF DISEASE, AND ANATOMIC LOCATION - p. 1106 99. Management of Extremity and Truncal Sarcoma - p. 1106 100. Management of Primary Localized Retroperitoneal Sarcoma - p. 1114 101. Serious Complications of Primary Treatment - p. 1117 102. Management of Specific Histologic Subtypes and Sites - p. 1124 103. FUTURE DIRECTIONS - p. 1126 104. 61. Sarcomas of Bone - p. 1141 105. 62. Cancer of the Skin - p. 1177 106. 63. Cutaneous Melanoma - p. 1205 107. INTRODUCTION - p. 1205 108. CLASSIFICATION OF MELANOMA SUBTYPES - p. 1205 109. MOLECULAR BIOLOGY OF MELANOMA - p. 1208 110. EPIDEMIOLOGY - p. 1212 111. CHANGES IN INCIDENCE - p. 1213 112. SEX AND AGE DISTRIBUTION - p. 1213 113. MELANOMA IN CHILDREN, INFANTS, AND NEONATES - p. 1213 114. ANATOMIC DISTRIBUTION - p. 1214 115. ETIOLOGY AND RISK FACTORS - p. 1214 116. PREVENTION AND SCREENING - p. 1215 117. DIAGNOSIS OF PRIMARY MELANOMA - p. 1217 118. GENERAL CONSIDERATIONS IN CLINICAL MANAGEMENT OF A NEWLY DIAGNOSED CUTANEOUS MELANOMA (STAGES I AND II) - p. 1220 119. CLINICAL TRIALS TO DEFINE MARGINS OF EXCISION FOR PRIMARY CUTANEOUS MELANOMAS - p. 1221 120. SURGICAL STAGING OF REGIONAL NODES - p. 1222 121. SELECTION OF PATIENTS FOR SENTINEL NODE BIOPSY - p. 1223 122. MANAGEMENT OF CLINICALLY LOCALIZED MELANOMA - p. 1223 123. THICK MELANOMAS (T4a, T4b, >4 MM THICK) - p. 1225 124. SPECIAL CONSIDERATIONS IN MANAGEMENT OF PRIMARY MELANOMAS - p. 1225 125. RADIOTHERAPY FOR A PRIMARY MELANOMA - p. 1227 126. CLINICAL FOLLOW-UP FOR INTERMEDIATE-THICKNESS AND THICK MELANOMAS (STAGE IB TO IIC) - p. 1228 127. REGIONALLY METASTATIC MELANOMA (STAGE III): LYMPH NODE METASTASIS, SATELLITE LESIONS, AND IN-TRANSIT METASTASES - p. 1228 128. ADJUVANT LYMPH NODE BASIN RADIOTHERAPY - p. 1233 129. NEOADJVUANT THERAPY IN MELANOMA - p. 1234 130. ADJUVANT SYSTEMIC THERAPY FOR STAGE III-IV AFTER SURGICAL RESECTION - p. 1236 131. MANAGEMENT OF DISTANT METASTASES OF MELANOMA (STAGE IV) - p. 1238 132. RADIATION THERAPY FOR OLIGOMETASTATIC MELANOMA - p. 1254 133. 64. Neoplasms of the Central Nervous System - p. 1263 134. EPIDEMIOLOGY OF BRAIN TUMORS - p. 1263 135. CLASSIFICATION AND PATHOLOGY - p. 1265 136. CLINICAL CONSIDERATIONS BY ANATOMIC LOCATION - p. 1266 137. NEURODIAGNOSTIC TESTS AND IMAGING - p. 1267 138. SURGERY - p. 1270 139. RADIATION THERAPY - p. 1271 140. SYSTEMIC TREATMENTS (CYTOTOXIC CHEMOTHERAPY, TARGETED AGENTS, AND IMMUNOTHERAPY) - p. 1273 141. SPECIFIC CENTRAL NERVOUS SYSTEM NEOPLASMS - p. 1276 142. GLIOMATOSIS CEREBRI - p. 1294 143. OPTIC, CHIASMAL, AND HYPOTHALAMIC GLIOMAS - p. 1294 144. BRAIN STEM GLIOMAS - p. 1296 145. CEREBELLAR ASTROCYTOMAS - p. 1297 146. GANGLIOGLIOMAS - p. 1299 147. EPENDYMOMA - p. 1300 148. MENINGIOMAS - p. 1300 149. Clinical and Pathologic Considerations - p. 1300 150. Surgery - p. 1301 151. Imaging - p. 1302 152. Radiation Therapy for Meningiomas - p. 1302 153. Stereotactic Radiosurgery - p. 1303 154. Chemotherapy - p. 1303 155. PRIMITIVE NEUROECTODERMAL OR EMBRYONAL CENTRAL NERVOUS SYSTEM NEOPLASMS - p. 1303 156. PINEAL REGION TUMORS AND GERM CELL TUMORS - p. 1308 157. PITUITARY ADENOMAS - p. 1309 158. CRANIOPHARYNGIOMAS - p. 1311 159. VESTIBULAR SCHWANNOMAS - p. 1312 160. GLOMUS JUGULARE TUMORS - p. 1314 161. HEMANGIOBLASTOMAS - p. 1314 162. CHORDOMAS AND CHONDROSARCOMAS - p. 1315 163. CHOROID PLEXUS TUMORS - p. 1318 164. SPINAL AXIS TUMORS - p. 1319 165. 65. Adolescents and Young Adults with Cancer - p. 1333 166. 66. Hodgkin Lymphoma - p. 1353 167. 67. Non-Hodgkin Lymphoma - p. 1371 168. INTRODUCTION - p. 1371 169. INCIDENCE AND ETIOLOGY - p. 1371 170. LYMPHOMA CLASSIFICATION: THE PRINCIPLES OF THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF LYMPHOID NEOPLASMS - p. 1375 171. DIFFERENTIAL DIAGNOSIS AND SITES OF DISEASE AT PRESENTATION - p. 1375 172. INITIAL MANAGEMENT - p. 1377 173. STAGING AND PROGNOSTIC SYSTEMS - p. 1377 174. SPECIFIC DISEASE ENTITIES - p. 1379 175. MATURE T-CELL AND NATURAL KILLER CELL NEOPLASMS - p. 1393 176. 68. Cutaneous Lymphomas - p. 1408 177. 69. Primary Central Nervous System Lymphoma - p. 1424 178. 70. Management of Acute Leukemias - p. 1437 179. 71. Chronic Myeloid Leukemia - p. 1457 180. 72. Chronic Lymphocytic Leukemias - p. 1471 181. 73. Myelodysplastic Syndromes - p. 1489 182. 74. Plasma Cell Neoplasms - p. 1509 183. 75. Cancer of Unknown Primary - p. 1546 184. 76. Benign and Malignant Mesothelioma - p. 1554 185. 77. Peritoneal Metastases and Peritoneal Mesothelioma - p. 1583 186. 78. Intraocular Melanoma - p. 1596 187. 79. Superior Vena Cava Syndrome - p. 1608 188. 80. Increased Intracranial Pressure - p. 1614 189. 81. Spinal Cord Compression - p. 1621 190. 82. Metabolic Emergencies - p. 1628 191. 83. Metastatic Cancer to the Brain - p. 1634 192. 84. Metastatic Cancer to the Lungs - p. 1647 193. 85. Metastatic Cancer to the Liver - p. 1659 194. 86. Metastatic Cancer to the Bone - p. 1672 195. 87. Malignant Pleural and Pericardial Effusions - p. 1681 196. 88. Malignant Ascites - p. 1689 197. 89. Paraneoplastic Syndromes - p. 1698 198. 90. Neutropenia and Thrombocytopenia - p. 1707 199. 91. Nausea and Vomiting - p. 1717 200. 92. Diarrhea and Constipation - p. 1728 201. 93. Oral Complications - p. 1738 202. 94. Cardiac Toxicity - p. 1753 203. 95. Gonadal Dysfunction - p. 1761 204. 96. Fatigue - p. 1774 205. 97. Neurocognitive Effects - p. 1784 206. 98. Management of Cancer Pain - p. 1791 207. 99. Nutrition Support - p. 1811 208. 100. Sexual Problems - p. 1819 209. 101. Psychiatric Distress and Resilience - p. 1829 210. 102. How We Talk to Patients and How We Talk to Ourselves - p. 1835 211. 103. Specialized Care of the Terminally Ill - p. 1840 212. Part IV Societal Issues - p. 1847 213. 104. Cancer Survivorship - p. 1848 214. 105. Minority Health and Cancer Health Disparities - p. 1857 215. 106. Virtual Care and Telehealth in Oncology - p. 1864 216. 107. Complementary, Alternative, and Integrative Therapies in Cancer Care - p. 1872 217. Index - p. I-1
No hay muestra disponible
No hay ficha técnica disponible
The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition.
1. INTRODUCTION - p. 439 2. EPIDEMIOLOGY - p. 439 3. ETIOLOGIC FACTORS AND PREDISPOSING CONDITIONS - p. 440 4. APPLIED ANATOMY AND HISTOLOGY - p. 442 5. NATURAL HISTORY AND PATTERNS OF FAILURE - p. 443 6. CLINICAL PRESENTATION - p. 444 7. DIAGNOSTIC STUDIES AND PRETREATMENT STAGING TOOLS - p. 444 8. STAGING GUIDELINES - p. 445 9. BIOMARKERS - p. 445 10. TREATMENT - p. 447 11. PREDICTORS OF TREATMENT RESPONSE - p. 464 12. PALLIATION OF ESOPHAGEAL CANCER WITH RADIATION THERAPY - p. 466 13. RADIOTHERAPY TECHNIQUES - p. 467 14. TREATMENT OF METASTATIC DISEASE - p. 469 15. 34. Cancer of the Stomach - p. 487 16. 35. Cancer of the Pancreas - p. 509 17. 36. Cancer of the Liver - p. 544 18. 37. Cancer of the Biliary Tree - p. 570 19. 38. Small Bowel Cancer - p. 590 20. 39. Gastrointestinal Stromal Tumor - p. 604 21. 40. Cancer of the Colon - p. 618 22. INTRODUCTION - p. 618 23. MOLECULAR BIOLOGY - p. 618 24. MULTISTEP MODELS OF COLORECTAL CANCER AND GENETIC INSTABILITY - p. 618 25. MUTATIONAL AND EPIGENETIC LANDSCAPES IN COLORECTAL CANCER - p. 618 26. ONCOGENE AND TUMOR SUPPRESSOR GENE MUTATIONS IN COLORECTAL CANCER PROGRESSION - p. 620 27. EPIDEMIOLOGY - p. 621 28. ETIOLOGY: GENETIC AND ENVIRONMENTAL RISK FACTORS - p. 622 29. FAMILIAL COLORECTAL CANCER - p. 625 30. ANATOMY OF THE COLON - p. 627 31. DIAGNOSIS OF COLORECTAL CANCER - p. 628 32. SCREENING FOR COLORECTAL CANCER - p. 629 33. STAGING AND PROGNOSIS OF COLORECTAL CANCER - p. 630 34. APPROACHES TO SURGICAL RESECTION OF COLON CANCER - p. 636 35. SURGICAL MANAGEMENT OF COMPLICATIONS FROM PRIMARY COLON CANCER - p. 639 36. LAPAROSCOPIC COLON RESECTION - p. 640 37. POLYPS AND STAGE I COLON CANCER - p. 641 38. STAGE II AND STAGE III COLON CANCER - p. 641 39. TREATMENT OF STAGE II PATIENTS - p. 644 40. TREATMENT OPTIONS FOR STAGE III PATIENTS - p. 647 41. INVESTIGATIONAL ADJUVANT APPROACHES - p. 648 42. FOLLOW-UP AFTER MANAGEMENT OF COLON CANCER WITH CURATIVE INTENT - p. 649 43. SURGICAL MANAGEMENT OF STAGE IV DISEASE - p. 650 44. MANAGEMENT OF UNRESECTABLE METASTATIC DISEASE - p. 651 45. MOLECULAR PREDICTIVE MARKERS - p. 667 46. 41. Cancer of the Rectum - p. 678 47. 42. Cancer of the Anal Region - p. 708 48. 43. Cancer of the Kidney - p. 729 49. 44. Cancer of the Bladder, Ureter, and Renal Pelvis - p. 756 50. 45. Cancer of the Prostate - p. 784 51. INTRODUCTION - p. 784 52. EPIDEMIOLOGY - p. 784 53. ANATOMY AND PATHOLOGY - p. 786 54. SCREENING - p. 791 55. DIAGNOSIS AND WORKUP - p. 792 56. RISK STRATIFICATION - p. 803 57. TREATMENT OF PROSTATE CANCER - p. 806 58. MANAGEMENT OF CLINICAL DISEASE STATES - p. 815 59. Clinically Localized Prostate Cancer - p. 815 60. Clinical Node Positive Disease - p. 821 61. Recurrent Prostate Cancer - p. 821 62. Metastatic Hormone-sensitive Disease - p. 822 63. Castrate-resistant Disease - p. 825 64. Variant Prostate Cancer - p. 830 65. Bone Supportive Agents - p. 831 66. FUTURE DIRECTIONS - p. 832 67. 46. Cancer of the Urethra and Penis - p. 846 68. 47. Cancer of the Testis - p. 856 69. 48. Cancer of the Cervix - p. 874 70. 49. Cancer of the Vagina and Vulva - p. 902 71. 50. Cancer of the Uterine Body - p. 917 72. 51. Gestational Trophoblastic Neoplasia - p. 935 73. 52. Ovarian Cancer - p. 941 74. 53. Malignant Tumors of the Breast - p. 968 75. INCIDENCE AND ETIOLOGY - p. 968 76. SCREENING AND PREVENTION FOR WOMEN AT HIGH RISK OF BREAST CANCER - p. 970 77. ANATOMY AND PATHOLOGY - p. 971 78. DIAGNOSIS AND BIOPSY - p. 975 79. STAGING - p. 976 80. MANAGEMENT BY STAGE: DUCTAL CARCINOMA IN SITU - p. 976 81. MANAGEMENT BY STAGE: PRIMARY OPERABLE INVASIVE BREAST CANCER - p. 982 82. MANAGEMENT BY STAGE: ADJUVANT SYSTEMIC THERAPY - p. 993 83. MANAGEMENT BY STAGE: SPECIAL CONSIDERATIONS - p. 999 84. MANAGEMENT BY STAGE: METASTATIC DISEASE - p. 1003 85. ACKNOWLEDGMENT - p. 1007 86. 54. Thyroid Tumors - p. 1019 87. 55. Parathyroid Tumors - p. 1032 88. 56. Adrenal Tumors - p. 1038 89. 57. Pancreatic Neuroendocrine Neoplasms - p. 1048 90. 58. Carcinoid Tumors and the Carcinoid Syndrome - p. 1064 91. 59. Multiple Endocrine Neoplasia - p. 1073 92. 60. Soft Tissue Sarcoma - p. 1080 93. INTRODUCTION - p. 1080 94. INCIDENCE AND ETIOLOGY - p. 1080 95. ANATOMIC AND AGE DISTRIBUTION AND PATHOLOGY - p. 1081 96. CLINICAL AND PATHOLOGIC FEATURES OF SPECIFIC SOFT TISSUE TUMOR TYPES - p. 1084 97. DIAGNOSIS AND STAGING - p. 1102 98. MANAGEMENT BY PRESENTATION STATUS, EXTENT OF DISEASE, AND ANATOMIC LOCATION - p. 1106 99. Management of Extremity and Truncal Sarcoma - p. 1106 100. Management of Primary Localized Retroperitoneal Sarcoma - p. 1114 101. Serious Complications of Primary Treatment - p. 1117 102. Management of Specific Histologic Subtypes and Sites - p. 1124 103. FUTURE DIRECTIONS - p. 1126 104. 61. Sarcomas of Bone - p. 1141 105. 62. Cancer of the Skin - p. 1177 106. 63. Cutaneous Melanoma - p. 1205 107. INTRODUCTION - p. 1205 108. CLASSIFICATION OF MELANOMA SUBTYPES - p. 1205 109. MOLECULAR BIOLOGY OF MELANOMA - p. 1208 110. EPIDEMIOLOGY - p. 1212 111. CHANGES IN INCIDENCE - p. 1213 112. SEX AND AGE DISTRIBUTION - p. 1213 113. MELANOMA IN CHILDREN, INFANTS, AND NEONATES - p. 1213 114. ANATOMIC DISTRIBUTION - p. 1214 115. ETIOLOGY AND RISK FACTORS - p. 1214 116. PREVENTION AND SCREENING - p. 1215 117. DIAGNOSIS OF PRIMARY MELANOMA - p. 1217 118. GENERAL CONSIDERATIONS IN CLINICAL MANAGEMENT OF A NEWLY DIAGNOSED CUTANEOUS MELANOMA (STAGES I AND II) - p. 1220 119. CLINICAL TRIALS TO DEFINE MARGINS OF EXCISION FOR PRIMARY CUTANEOUS MELANOMAS - p. 1221 120. SURGICAL STAGING OF REGIONAL NODES - p. 1222 121. SELECTION OF PATIENTS FOR SENTINEL NODE BIOPSY - p. 1223 122. MANAGEMENT OF CLINICALLY LOCALIZED MELANOMA - p. 1223 123. THICK MELANOMAS (T4a, T4b, >4 MM THICK) - p. 1225 124. SPECIAL CONSIDERATIONS IN MANAGEMENT OF PRIMARY MELANOMAS - p. 1225 125. RADIOTHERAPY FOR A PRIMARY MELANOMA - p. 1227 126. CLINICAL FOLLOW-UP FOR INTERMEDIATE-THICKNESS AND THICK MELANOMAS (STAGE IB TO IIC) - p. 1228 127. REGIONALLY METASTATIC MELANOMA (STAGE III): LYMPH NODE METASTASIS, SATELLITE LESIONS, AND IN-TRANSIT METASTASES - p. 1228 128. ADJUVANT LYMPH NODE BASIN RADIOTHERAPY - p. 1233 129. NEOADJVUANT THERAPY IN MELANOMA - p. 1234 130. ADJUVANT SYSTEMIC THERAPY FOR STAGE III-IV AFTER SURGICAL RESECTION - p. 1236 131. MANAGEMENT OF DISTANT METASTASES OF MELANOMA (STAGE IV) - p. 1238 132. RADIATION THERAPY FOR OLIGOMETASTATIC MELANOMA - p. 1254 133. 64. Neoplasms of the Central Nervous System - p. 1263 134. EPIDEMIOLOGY OF BRAIN TUMORS - p. 1263 135. CLASSIFICATION AND PATHOLOGY - p. 1265 136. CLINICAL CONSIDERATIONS BY ANATOMIC LOCATION - p. 1266 137. NEURODIAGNOSTIC TESTS AND IMAGING - p. 1267 138. SURGERY - p. 1270 139. RADIATION THERAPY - p. 1271 140. SYSTEMIC TREATMENTS (CYTOTOXIC CHEMOTHERAPY, TARGETED AGENTS, AND IMMUNOTHERAPY) - p. 1273 141. SPECIFIC CENTRAL NERVOUS SYSTEM NEOPLASMS - p. 1276 142. GLIOMATOSIS CEREBRI - p. 1294 143. OPTIC, CHIASMAL, AND HYPOTHALAMIC GLIOMAS - p. 1294 144. BRAIN STEM GLIOMAS - p. 1296 145. CEREBELLAR ASTROCYTOMAS - p. 1297 146. GANGLIOGLIOMAS - p. 1299 147. EPENDYMOMA - p. 1300 148. MENINGIOMAS - p. 1300 149. Clinical and Pathologic Considerations - p. 1300 150. Surgery - p. 1301 151. Imaging - p. 1302 152. Radiation Therapy for Meningiomas - p. 1302 153. Stereotactic Radiosurgery - p. 1303 154. Chemotherapy - p. 1303 155. PRIMITIVE NEUROECTODERMAL OR EMBRYONAL CENTRAL NERVOUS SYSTEM NEOPLASMS - p. 1303 156. PINEAL REGION TUMORS AND GERM CELL TUMORS - p. 1308 157. PITUITARY ADENOMAS - p. 1309 158. CRANIOPHARYNGIOMAS - p. 1311 159. VESTIBULAR SCHWANNOMAS - p. 1312 160. GLOMUS JUGULARE TUMORS - p. 1314 161. HEMANGIOBLASTOMAS - p. 1314 162. CHORDOMAS AND CHONDROSARCOMAS - p. 1315 163. CHOROID PLEXUS TUMORS - p. 1318 164. SPINAL AXIS TUMORS - p. 1319 165. 65. Adolescents and Young Adults with Cancer - p. 1333 166. 66. Hodgkin Lymphoma - p. 1353 167. 67. Non-Hodgkin Lymphoma - p. 1371 168. INTRODUCTION - p. 1371 169. INCIDENCE AND ETIOLOGY - p. 1371 170. LYMPHOMA CLASSIFICATION: THE PRINCIPLES OF THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF LYMPHOID NEOPLASMS - p. 1375 171. DIFFERENTIAL DIAGNOSIS AND SITES OF DISEASE AT PRESENTATION - p. 1375 172. INITIAL MANAGEMENT - p. 1377 173. STAGING AND PROGNOSTIC SYSTEMS - p. 1377 174. SPECIFIC DISEASE ENTITIES - p. 1379 175. MATURE T-CELL AND NATURAL KILLER CELL NEOPLASMS - p. 1393 176. 68. Cutaneous Lymphomas - p. 1408 177. 69. Primary Central Nervous System Lymphoma - p. 1424 178. 70. Management of Acute Leukemias - p. 1437 179. 71. Chronic Myeloid Leukemia - p. 1457 180. 72. Chronic Lymphocytic Leukemias - p. 1471 181. 73. Myelodysplastic Syndromes - p. 1489 182. 74. Plasma Cell Neoplasms - p. 1509 183. 75. Cancer of Unknown Primary - p. 1546 184. 76. Benign and Malignant Mesothelioma - p. 1554 185. 77. Peritoneal Metastases and Peritoneal Mesothelioma - p. 1583 186. 78. Intraocular Melanoma - p. 1596 187. 79. Superior Vena Cava Syndrome - p. 1608 188. 80. Increased Intracranial Pressure - p. 1614 189. 81. Spinal Cord Compression - p. 1621 190. 82. Metabolic Emergencies - p. 1628 191. 83. Metastatic Cancer to the Brain - p. 1634 192. 84. Metastatic Cancer to the Lungs - p. 1647 193. 85. Metastatic Cancer to the Liver - p. 1659 194. 86. Metastatic Cancer to the Bone - p. 1672 195. 87. Malignant Pleural and Pericardial Effusions - p. 1681 196. 88. Malignant Ascites - p. 1689 197. 89. Paraneoplastic Syndromes - p. 1698 198. 90. Neutropenia and Thrombocytopenia - p. 1707 199. 91. Nausea and Vomiting - p. 1717 200. 92. Diarrhea and Constipation - p. 1728 201. 93. Oral Complications - p. 1738 202. 94. Cardiac Toxicity - p. 1753 203. 95. Gonadal Dysfunction - p. 1761 204. 96. Fatigue - p. 1774 205. 97. Neurocognitive Effects - p. 1784 206. 98. Management of Cancer Pain - p. 1791 207. 99. Nutrition Support - p. 1811 208. 100. Sexual Problems - p. 1819 209. 101. Psychiatric Distress and Resilience - p. 1829 210. 102. How We Talk to Patients and How We Talk to Ourselves - p. 1835 211. 103. Specialized Care of the Terminally Ill - p. 1840 212. Part IV Societal Issues - p. 1847 213. 104. Cancer Survivorship - p. 1848 214. 105. Minority Health and Cancer Health Disparities - p. 1857 215. 106. Virtual Care and Telehealth in Oncology - p. 1864 216. 107. Complementary, Alternative, and Integrative Therapies in Cancer Care - p. 1872 217. Index - p. I-1
No hay muestra disponible
No hay ficha técnica disponible
